

## MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

## HIGHLIGHTS

**453** Selected Articles from This Issue

## REVIEW

**455** **Salting the Soil: Targeting the Microenvironment of Brain Metastases**

**A C** Ethan S. Srinivasan, Aaron C. Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M. Ashley, Peter E. Fecci, and Mustafa Khasraw

## SMALL MOLECULE THERAPEUTICS

**467** **Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor**

Aaron Balog, Tai-an Lin, Derrick Maley, Johnni Gullo-Brown, Enzo Hamza Kandoussi, Jianing Zeng, and John T. Hunt

**477** **A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers**

**A C** Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Xiuxia Liu, Cheng-Hsin Wei, Jason Roszik, Adam S. Kittai, Alexey V. Danilov, Xiaoshan Zhang, Bingliang Fang, Jing Wang, John V. Heymach, Liliya Tyutyunyk-Massey, Sarah J. Freemantle, Jonathan M. Kurie, Xi Liu, and Ethan Dmitrovsky

**490** **Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy**

Geun Taek Lee, Naoya Nagaya, Jenny Desantis, Kiran Madura, Hatem E. Sabaawy, Wun-Jae Kim, Roy J. Vaz, Gabriele Cruciani, and Isaac Yi Kim

**500** **The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies**

Sruthy Varghese, Snigdha Pramanik, Leila J. Williams, Hannah R. Hodges, Courtney W. Hudgens, Grant M. Fischer, Catherine K. Luo, Barbara Knighton, Lin Tan, Philip L. Lorenzi, Andrew L. Mackinnon, Jennifer L. McQuade, Yared Hailemichael, Jason Roszik, Weiyi Peng, and Y.N. Vashisht Gopal

**512** **Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX**

Jacopo Millul, Christiane Krudewig, Aureliano Zana, Sheila Dakhel Plaza, Emanuele Puca, Alessandra Villa, Dario Neri, and Samuele Cazzamalli

## LARGE MOLECULE THERAPEUTICS

**523** **Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12**

**A C** Nuruddeen D. Lewis, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Tong Zi, Ke Xu, Kevin Dooley, Su Chul Jang, Bryan Choi, Adam Boutin, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Michael Doherty, Leonid Gaidukov, Scott Estes, Kyriakos D. Economides, Douglas E. Williams, and Sriram Sathyanarayanan

**535** **ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium**

**A C** Pooja Hingorani, Michael E. Roth, Yifei Wang, Wendong Zhang, Jonathan B. Gill, Douglas J. Harrison, Beverly Teicher, Stephen Erickson, Gregory Gatto, Malcolm A. Smith, Edward A. Kolb, and Richard Gorlick

**541** **Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR**

**A C** Shenlan Mao, Raghothama Chaerkady, Wen Yu, Gina D'Angelo, Andrew Garcia, Hong Chen, Allison M. Barrett, Sandrina Phipps, Ryan Fleming, Sonja Hess, Jens-Oliver Koopmann, Nazzareno Dimasi, Susan Wilson, Kathryn Pugh, Kimberly Cook, Luke A. Masterson, Changshou Gao, Herren Wu, Ronald Herbst, Philip W. Howard, David A. Tice, Mark Cobbold, and Jay Harper

# TABLE OF CONTENTS

**553 Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties**

William H. Gmeiner, Anthony Dominijanni, Alex O. Haber, Lais P. Ghiraldeli, David L. Caudell, Ralph D'Agostino Jr, Boris C. Pasche, Thomas L. Smith, Zhiyong Deng, Sezgin Kiren, Chinnadurai Mani, Komaraiah Palle, and Jonathan R. Brody

## COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

**564 Identification of Predictive *ERBB* Mutations by Leveraging Publicly Available Cell Line Databases**

Marika K.A. Koivu, Deepankar Chakroborty, Mahlet Z. Tamirat, Mark S. Johnson, Kari J. Kurppa, and Klaus Elenius

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

**577 Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells**

**AC** Yida Zhang, Lile He, Ananthan Sadagopan, Tao Ma, Gianpietro Dotti, Yufeng Wang, Hui Zheng, Xin Gao, Dian Wang, Albert B. DeLeo, Song Fan, Ruochuan Sun, Ling Yu, Liyuan Zhang, Gongxian Wang, Soldano Ferrone, and Xinhui Wang

**589 Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors**

Amy Kwan, Natalie Winder, Emer Atkinson, Haider Al-Janabi, Richard J. Allen, Russell Hughes, Mohammed Moamin, Rikah Louie, Dhanajay Evans, Matthew Hutchinson, Drew Capper, Katie Cox, Joshua Handley, Adam Wilshaw, Taewoo Kim, Simon J. Tazzyman, Sanjay Srivastava, Penelope Ottewell, Jayakumar Vadakekolathu, Graham Pockley, Claire E. Lewis, Janet E. Brown, Sarah J. Danson, Joe Conner, and Munitta Muthana

**602 Neutralization of TGF $\beta$  Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma**

Brandon M. Roane, Selene Meza-Perez, Ashwini A. Katre, Whitney N. Goldsberry, Troy D. Randall, Lyse A. Norian, Michael J. Birrer, and Rebecca C. Arend

**612 The Histone Methyltransferase Gene *G9A* Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells**


Rupesh Shrestha, Kumaravel Mohankumar, Un-ho Jin, Gregory Martin, and Stephen Safe

**AC** AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

Photomicrographic image of a tumor invasive margin from a syngeneic tumor model (MC38) stained with multiplex immunofluorescence to identify macrophages (F4/80<sup>+</sup>; Red) in the tumor microenvironment. Polarization state of these macrophages was determined using inducible nitric oxide synthase (iNOS; Green), a marker for M1 polarization, and arginase I (Arg1; Cyan) a marker for M2 polarization. In the tumor margins, 152-fold increase in M1 macrophages were observed with exoIL-12 treatment. These studies provide evidence that exoIL-12 was significantly more potent than rIL12 and enabled systemic anti-tumor immunity by facilitating prolonged local pharmacology and undetectable systemic exposure. The improved therapeutic index achieved in pre-clinical models support further clinical investigation of this powerful cytokine. Read the full article on p. 523.



# Molecular Cancer Therapeutics

**20 (3)**

*Mol Cancer Ther* 2021;20:453-622.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/20/3>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/3>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.